2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
5
Solid Tumor
1
Sarcoma
1
Ovarian Cancer Recurrent
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumors
1
Advanced Neoplastic Disease
1
Interventions
Paclitaxel
4
liposomal doxorubicin
3
Carboplatin
3
pembrolizumab
2
Bevacizumab
2
1-dodecylpyridoxal
2
poly(I).poly(c12,U)
1
mirabegron
1
disitamab vedotin
1
apatinib
1
anlotinib
1
Tocotrienols
1
Platinum Compounds
1
Lenalidomide
1
Interferon alpha-2
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gemcitabine
1
EP-100 membrane-disrupting peptide
1
Cisplatin
1
AC 7700
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Cancer Recurrent
×
AC 7700
×
Clear all
NCT01332656
2015-12-21
OPSALIN
Sanofi
Phase 2
Completed
154 enrolled